BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
BioMarin Pharmaceutical Inc. (BMRN)
- Home
- About Us
- Philosophy
- Stocks
- Currencies
- Real Estates
- Commodities
- Entrepreneurship
- Useful Info
- Help
BioMartin has been losing money and will lose in the coming years.
What is terribel is that the CEO has been selling its stocks more recently, and consistently ! read at
https://sportsperspectives.com/2017/01/05/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sells-8000-shares-of-stock/
Sell !